Results 51 to 60 of about 12,783,707 (261)

HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer

Tumor Biology, 2017
Emerging evidence has demonstrated that the high expression of HBXIP has been correlated with many cancers. With evaluation of the functional role of HBXIP in non-small-cell lung cancer, the primary aim of this study is to investigate the correlation ...
Yixuan Wang, Nan Li, Shuanlong Che, Tiefeng Jin, Junjie Piao, Shuangping Liu, Zhenhua Lin   +6 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Chinese Expert Consensus on Assessment and Clinical Application of 
Tertiary Lymphoid Structure for Non-small Cell Lung Cancer (2025 Version)

Chinese Journal of Lung Cancer
The tertiary lymphoid structure (TLS) plays a crucial role in the tumor microenvironment, influencing tumor development and progression. As an emerging biomarker for predicting the prognosis and treatment response in cancer patients, TLS has received ...
Lung Cancer Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology   +1 more
doaj   +1 more source

MiR-222-3p Promotes Cell Proliferation and Inhibits Apoptosis by Targeting PUMA (BBC3) in Non-Small Cell Lung Cancer

Technology in Cancer Research & Treatment, 2020
MicroRNAs have been demonstrated to be critical regulators in tumor progression, including non-small cell lung cancer. MicroRNA-222-3p has been reported to function as a tumor suppressor or oncogene in several types of cancer, but its function role in ...
Weijun Chen MM, Xiaobo Li MM
doaj   +1 more source

Opposite role of Kindlin-1 and Kindlin-2 in lung cancers. [PDF]

PLoS ONE, 2012
Lung cancer is highly heterogenous and is composed of various subtypes that are in diverse differential stages. The newly identified integrin-interacting proteins Kindlin-1 and Kindlin-2 are the activators of transmembrane receptor integrins that play ...
Jun Zhan, Xiang Zhu, Yongqing Guo, Yunling Wang, Yuxiang Wang, Guangliang Qiang, Miaomiao Niu, Jinxia Hu, Juan Du, Zhilun Li, Jia Cui, Bo Ma, Weigang Fang, Hongquan Zhang   +13 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Comparison of platinum and non-platinum based regimens in the treatment of small cell lung cancer

, 2023
Small cell lung cancer, and lung cancer in general, remains one of the most impactful public health issues in the modern age due to its high morbidity and mortality.
Benyarko, Ato
core  

Deep sequence analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations [PDF]

, 2012
KRAS mutations are highly prevalent in non-small cell lung cancer (NSCLC), and tumors harboring these mutations tend to be aggressive and resistant to chemotherapy.
David Rossell, Xiaojia eTang, Tang, Xiaojia, Hossain, Asif, Rossell, David, Asha Nair, Jean-Pierre Kocher, Chai, High-Seng, Michael P. Walsh, Asif eHossain, Yan W. Asmann, Baker, Tiffany R., Edith A. Perez, Kalari, Krishna R., Necela, Brian M., Alan P. Fields, High Seng eChai, Xiaojia Tang, Alan P Fields, Leontovich, Alexey A., Carr, Jennifer, Thompson, E. Aubrey, Saurabh Baheti, Kocher, Jean-Pierre, Tiffany R Baker, Younkin, Curtis S., Walsh, Michael P., E. Aubrey Thompson, Jennifer M. Kachergus, Jennifer M Kachergus, Jennifer M Carr, Fields, Alan P., Asmann, Yan W., Krishna R. Kalari, E. Aubrey eThompson, Kachergus, Jennifer M., Steven N Hart, Krishna R Kalari, Jennifer M. Carr, David eRossell, Saurabh eBaheti, Steven N. Hart, Curtis S. Younkin, Zhifu eSun, Edith A Perez, Tiffany Baker, Brian M Necela, Alexey A. Leontovich, Nair, Asha, Perez, Edith A., Sun, Zhifu, Reisman, David N., Jean-Pierre eKocher, Asha eNair, Hart, Steven N., Yan W Asmann, Zhifu Sun, Michael eWalsh, Baheti, Saurabh, David N Reisman, Brian M. Necela, High-Seng Chai, David N. Reisman, Alexey A Leontovich, Asif Hossain, Curtis S Younkin   +65 more
core   +1 more source

External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification

Frontiers in Oncology
IntroductionIn the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.MethodsResected pT1/2 PM patients were ...
Zheng Liu, Zheng Liu, Zheng Liu, Zheng Liu, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Yun Li, Yun Li, Wenhan Weng, Wenhan Weng   +11 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source